Pfizer/Boehringer Spiriva Clears FDA For COPD; Launch Set For Summer
Executive Summary
Pfizer/Boehringer Ingelheim's marketing plan for Spiriva will emphasize the drug's long-term efficacy compared to other COPD therapies
You may also be interested in...
UnitedHealth Rx Registry Will Test Four Highest Prescribed NMEs In 2004
UnitedHealth is testing its new postmarketing surveillance drug database on the four most frequently prescribed new molecular entities launched in 2004
UnitedHealth Rx Registry Will Test Four Highest Prescribed NMEs In 2004
UnitedHealth is testing its new postmarketing surveillance drug database on the four most frequently prescribed new molecular entities launched in 2004
Pfizer/Boehringer Spiriva Launched At 30% Discount To Advair For COPD
Pfizer and Boehringer Ingelheim are launching the chronic obstructive pulmonary disease therapy Spiriva at a 30% discount to the average wholesale price of GlaxoSmithKline's Advair